Generated by AI
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company is centered on complement-targeting science, with a portfolio of monoclonal antibodies and fusion proteins designed to selectively modulate immune pathways involved in disease activity. Its lead programs include claseprubart, an engineered antibody designed to inhibit the active C1s complement protein, and DNTH212, a bifunctional fusion protein that combines immune-cell targeting with suppression of B-cell signaling. Dianthus Therapeutics Inc. is advancing these candidates for conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company’s role in the market is to develop differentiated antibody-based treatments aimed at patients with serious immune-mediated disorders that have limited therapeutic options.
Website7 Times Square
New York, NY, 10036
United States
The latest articles about DNTH.
Dianthus Therapeutics has turned into a striking outperformer, with a very large 3 year gain putting fresh attention on whether the share price still lines up with what its balance sheet supports. With that kind of move already on the table, the question now is how today’s valuation stacks up against the book value sitting behind each share. Over the past 3 years the stock has returned roughly 7x, which puts a lot of weight on whether the current market value can be explained by what the...
Summary of Jun 28's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Summary of Jun 28's posts. Generated by AI.
Investors talking about DNTH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.